Stefan Weber, CEO of Newron Pharmaceuticals discusses how his company works with Rett Syndrome advocacy groups. Newron is focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system.
Xadago (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the US. Newron also has a pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome. This discussion focuses on Rett syndrome.